About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2025 Cellectis Investors R&D Day
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2025
2024
2023
2022
2021
2020
19
Nov 2025
06:20 E.S.T.
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
Read more
07
Nov 2025
16:30 E.S.T.
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
Read more
03
Nov 2025
09:15 E.S.T.
Cellectis to Present a Development Update for eti-cel at ASH 2025
Read more
31
Oct 2025
16:30 E.S.T.
Cellectis to Report Third Quarter Financial Results on November 7, 2025
Read more
16
Oct 2025
15:00 E.S.T.
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
Read more
16
Oct 2025
07:00 E.S.T.
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
Read more
1
2
3
Next